Product
Panzyga
5 clinical trials
9 indications
Indication
Chronic Lymphocytic LeukemiaIndication
HypogammaglobulinemiaIndication
Immune ThrombocytopeniaIndication
Small Fiber NeuropathyIndication
Autoimmune Small Fiber NeuropathyIndication
Inflammatory PolyneuropathyIndication
Immune-Mediated NeuropathyClinical trial
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) PatientsStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)Status: Terminated, Estimated PCD: 2024-05-29
Clinical trial
Intravenous Immunoglobulin (IVIG) in the Treatment of Small Fiber Neuropathy Due to TS-HDS, FGFR-3, or Plexin D1 Antibodies: a Double Blinded Placebo-controlled Phase II TrialStatus: Recruiting, Estimated PCD: 2026-12-01